Glioma Stem Cells and their Therapy ResistanceRoss Mangum1 and Ichiro Nakano2*
- *Corresponding Author:
- Dr. Ichiro Nakano Ph.D
Dardinger Laboratory for Neurosciences
Department of Neurological Surgery
OSU Medical Center, 385-A Wiseman Hall
400 W. 12th Ave, Columbus, OH 43210
E-mail: [email protected]
Received date: May 30, 2011; Accepted date: June 17, 2011; Published date: June 20, 2011
Citation: Mangum R, Nakano I (2011) Glioma Stem Cells and their Therapy Resistance. J Carcinogene Mutagene S1:002. doi: 10.4172/2157-2518.S1-002
Copyright: © 2011 Mangum R, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Glioblastoma multiforme (GBM) is the most highly invasive and malignant primary brain tumor in humans with
median survival after diagnosis as low as 12-15 months. The poor prognosis of GBM is attributable to its resistance
to current therapeutic approaches, consisting of maximal debulking surgery, chemotherapy with temozolomide,
and radiotherapy. Amongst the heterogeneous population of tumor cells found in GBM, a self-renewing and
proliferating cell type known as glioma stem-like cells (GSC) has been identified as a potential source for glioma
therapy resistance. It has been well documented that current therapies fail to effectively eliminate GSC from the
tumor population. This contributes to the virtually inevitable tumor recurrence in GBM patients following treatment.
Therefore, GSC provide a particularly attractive target for the development of future therapies. This review highlights
several proposed mechanisms behind therapy resistant glioma cells including DNA repair mechanisms, cell cycle
checkpoints, drug efflux processes, and the role of the tumor microenvironment. Furthermore, several therapeutic
strategies to target genes or pathways specific to GSC survival and proliferation will be discussed.